Synergistic effects of atorvastatin and rosiglitazone on endothelium protection in rats with dyslipidemia

Lipids in Health and Disease

Zhi-Peng Zou²  Bei Sun¹  Wen-Ju Yan³  Wei-Li Zhang¹ 

[1] Department of Cardiology, Yantaishan Hospital, Yantai, Shandong Province 264001, China;Department of Cardiology, Hospital of Economic and Technological Development Zone, Yantai, Shandong Province 264001, China;Department of Cardiology, Central Hospital of Taian, Taian, Shandong Province 271000, China

关键词: Inflammation;    Oxidative stress;    Endothelial dysfunction;    Dyslipidemia;   

Others  :  1145649
DOI  :  10.1186/1476-511X-13-168

 received in 2014-07-10, accepted in 2014-10-16,  发布年份 2014

【 摘 要 】

Background

Endothelial dysfunction is implicated in the initiation and progression of atherosclerosis. Whether atorvastatin combined with rosiglitazone has synergistic effects on endothelial function improvement in the setting of dyslipidemia is unknown.

Methods

Dyslipidemia rat model was produced with high-fat and high-cholesterol diet administration. Thereafter, atorvastatin, rosiglitazone or atorvastatin combined with rosiglitazone were prescribed for 2 weeks. At baseline, 6 weeks of dyslipidemia model production, and 2 weeks of medical intervention, fasting blood was drawn for parameters of interest evaluation. At the end, myocardium was used for 15-deoxy-delta-12,14-PGJ₂ (15-d-PGJ₂) assessment.

Results

Initially, there was no significant difference of parameters between sham and dyslipidemia groups. With 6 weeks’ high-fat and high-cholesterol diet administration, as compared to sham group, serum levels of triglyceride (TG), total cholesterol (TC) and low density lipoprotein-cholesterol (LDL-C) were significantly increased. Additionally, nitric oxide (NO) production was reduced and serum levels of malondialdehyde (MDA), C-reactive protein (CRP) and asymmetric dimethylarginine (ADMA) were profoundly elevated in dyslipidemia group. After 2 weeks’ medical intervention, lipid profile was slightly improved in atorvastatin and combined groups as compared to control group. Nevertheless, in comparison to control group, NO production was profoundly increased and serum levels of MDA, CRP and ADMA were significantly decreased with atorvastatin or rosiglitazone therapy. 15-d-PGJ₂ expression of myocardium was also significantly elevated with atorvastatin or rosiglitazone treatment. Notably, these effects were further enhanced with combined therapy, suggesting that atorvastatin and rosiglitazone had synergistic effects on endothelial protection, and inflammation and oxidation amelioration.

Conclusion

Atorvastatin and rosiglitazone therapy had synergistic effects on endothelium protection as well as amelioration of oxidative stress and inflammatory reaction in rats with dyslipidemia.

【 授权许可】

   
2014 Zhang et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, et al.: Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 2014, 129:e28-28e292.
• [2]Stone NJ, Robinson JG, Lichtenstein AH, Goff DC Jr, Lloyd-Jones DM, Smith SC Jr, Blum C, Schwartz JS: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129:S1-1S45.
• [3]Meyrelles SS, Peotta VA, Pereira TM, Vasquez EC: Endothelial dysfunction in the apolipoprotein E-deficient mouse: insights into the influence of diet, gender and aging. Lipids Health Dis 2011, 10:211. BioMed Central Full Text
• [4]Hirase T, Node K: Endothelial dysfunction as a cellular mechanism for vascular failure. Am J Physiol Heart Circ Physiol 2012, 302:H499-H505.
• [5]Grassi D, Desideri G, Ferri C: Cardiovascular risk and endothelial dysfunction: the preferential route for atherosclerosis. Curr Pharm Biotechnol 2011, 12:1343-1353.
• [6]Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP: Lipid lowering agents and the endothelium: an update after 4 years. Curr Vasc Pharmacol 2012, 10:33-41.
• [7]Balakumar P, Kathuria S, Taneja G, Kalra S, Mahadevan N: Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins. J Mol Cell Cardiol 2012, 52:83-92.
• [8]Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C: Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012, 18:1519-1530.
• [9]Grip O, Janciauskiene S, Lindgren S: Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm Res 2002, 51:58-62.
• [10]Mulhaupt F, Matter CM, Kwak BR, Pelli G, Veillard NR, Burger F, Graber P, Luscher TF, Mach F: Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 2003, 59:755-766.
• [11]Francis GA, Annicotte JS, Auwerx J: PPAR agonists in the treatment of atherosclerosis. Curr Opin Pharmacol 2003, 3:186-191.
• [12]Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL, Ohlstein EH, Jucker BM: Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005, 54:554-562.
• [13]Chen T, Jin X, Crawford BH, Cheng H, Saafir TB, Wagner MB, Yuan Z, Ding G: Cardioprotection from oxidative stress in the newborn heart by activation of PPARgamma is mediated by catalase. Free Radic Biol Med 2012, 53:208-215.
• [14]Huang C, Cen C, Wang C, Zhan H, Ding X: Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia. Lipids Health Dis 2014, 13:67. BioMed Central Full Text
• [15]Tietge UJ: Hyperlipidemia and cardiovascular disease: inflammation, dyslipidemia, and atherosclerosis. Curr Opin Lipidol 2014, 25:94-95.
• [16]Hasan ST, Zingg JM, Kwan P, Noble T, Smith D, Meydani M: Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice. Atherosclerosis 2014, 232:40-51.
• [17]Jasinska M, Owczarek J, Orszulak-Michalak D: Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 2007, 59:483-499.
• [18]Molavi B, Chen J, Mehta JL: Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. Am J Physiol Heart Circ Physiol 2006, 291:H687-H693.
• [19]Gonon AT, Bulhak A, Labruto F, Sjoquist PO, Pernow J: Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide. Basic Res Cardiol 2007, 102:80-89.
• [20]Mersmann J, Tran N, Zacharowski PA, Grotemeyer D, Zacharowski K: Rosiglitazone is cardioprotective in a murine model of myocardial I/R. Shock 2008, 30:64-68.
• [21]Palee S, Weerateerangkul P, Surinkeaw S, Chattipakorn S, Chattipakorn N: Effect of rosiglitazone on cardiac electrophysiology, infarct size and mitochondrial function in ischaemia and reperfusion of swine and rat heart. Exp Physiol 2011, 96:778-789.
• [22]Calnek DS, Mazzella L, Roser S, Roman J, Hart CM: Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003, 23:52-57.
• [23]Nicol CJ, Adachi M, Akiyama TE, Gonzalez FJ: PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am J Hypertens 2005, 18:549-556.
• [24]Bishop-Bailey D: Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 2000, 129:823-834.
• [25]Ren Y, Sun C, Sun Y, Tan H, Wu Y, Cui B, Wu Z: PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation. Vascul Pharmacol 2009, 51:169-174.
• [26]Chen R, Liang F, Moriya J, Yamakawa J, Takahashi T, Shen L, Kanda T: Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: are the reagents beneficial or harmful. Int J Cardiol 2008, 130:131-139.
• [27]Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B: Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007, 1771:1065-1081.
• [28]Shibata T, Kondo M, Osawa T, Shibata N, Kobayashi M, Uchida K: 15-deoxy-delta 12,14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes. J Biol Chem 2002, 277:10459-10466.
• [29]Kim JB, Wright HM, Wright M, Spiegelman BM: ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci U S A 1998, 95:4333-4337.